PCM 075

Drug Profile

PCM 075

Alternative Names: NMS-1286937; NMS-P937; PCM075

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; TrovaGene
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Feb 2018 Pharmacodynamics data from a preclinical trial in Prostate cancer released by Trovagene
  • 25 Jan 2018 Phase-II clinical trials in Prostate cancer (Combination therapy, Second-line therapy or greater, Metastatic disease; Hormone-refractory) in USA (PO) (NCT03414034)
  • 14 Dec 2017 Trovagene plans a phase II trial for Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top